THE EFFECT OF VITAMIN E (α-TOCOPHEROL) TO TNF-α SERUM LEVELS IN WISTAR WHITE STRAIN RATS EXPOSED TO CISPLATIN

Eldien Muhammad Shidqy, Doddy M. Soebadi, Lukman Hakim.

Department of Urology, Faculty of Medicine/Universitas Airlangga, Soetomo General Hospital, Surabaya.

ABSTRACT

Objective: To analyze the protective effect of vitamin E on TNF-α levels in white Wistar strains exposed to Cisplatin.

Material & Methods: The design of this study was an experimental laboratory with post-test only control group design, with the evaluation of TNF-α levels carried out after the animals were treated. The grouping of experimental animals was carried out by randomization. This study used male Wistar white rats as samples. The control group in this study included a negative control group (CN), which was given an injection of 1 cc intravenous normal saline 0.9% on the 7th day as a placebo, then on the 10th day the blood sample was taken. The positive control group (CP), which was given cisplatin treatment at a dose of 5 mg/kg intraperitoneally, once on the 7th day. Treatment group (P1) was treated using cisplatin 5 mg/kg intra-peritoneally and Vitamin E 100 mg/KgBW, and Treatment group (P2) was treated using cisplatin 5 mg/kg intra-peritoneally and Vitamin E 200 mg/KgBW. Blood samples were taken on the 10th day, intra-cardiac and TNF-α levels were analyzed using ELISA.

Results: There were significant differences in the mean TNF-α levels in the negative control group for all treatment groups with a p-value <0.05. There was also a significant difference in TNF-α levels in the positive control group for treatment group 1 and treatment 2 with p<0.05. On the other hand, further analysis showed that there was no significant difference between treatment group 1 and treatment group 2 (p>0.05).

Conclusion: TNF-α levels in mice given cisplatin was much higher compared with the control group. Vitamin E 100 and 200 mg/kgBW cause a decrease in TNF-α protein levels in mice injected with cisplatin when compared with controls. There is no difference in TNF-α levels in mice receiving vitamin E at doses of 100 and 200 mg/kgBW.

Keywords: Cisplatin, TNF-α, vitamin E.
INTRODUCTION

Cancer is the second highest cause of death globally, with an estimated 9.6 million cancer deaths in 2018. Bladder cancer is the 7th most common malignancy in men and 17th in women. The worldwide incidence is 9 per 100,000 for men and 2 per 100,000 for women.\(^1\) The incidence of bladder cancer in Indonesia is not known certainly. According to GLOBOCAN data in 2008, the incidence in Indonesia reached 5.8 per 100,000 population. One of the therapies in cancer is chemotherapy. Cisplatin is one of the most widely used chemotherapy including malignancies in urology: bladder cancer, testicular cancer, penile cancer, and several other cancers. Cisplatin is the first-line chemotherapy in solid tumour. One mechanism by which cisplatin is effective against solid tumour is through the effects of proapoptotic.\(^2\) An important side effect of cisplatin is acute kidney failure; it is estimated that one third of patients are proven to have kidney dysfunction due to cisplatin therapy.\(^3\) Although there are several strategies to prevent nephrotoxicity from cisplatin, no specific treatment recommendations are available to date.

The pathophysiology of acute kidney failure induced by cisplatin is associated with damage to the renal proximal tubules and fundamental mechanisms such as oxidative stress, inflammation, and vascular damage. Recent studies have focused on tubular cell apoptosis and many apoptotic pathways, including tumour necrosis factor receptors (TNFs) or extrinsic pathways, mitochondrial intestinal pathways (Bax pathways) that are controlled by Bel-2 exits, and endoplasmic stress reticulum pathways, have been described as correlated with renal tubular cell death.\(^3\)

Vitamin E (\(\alpha\)-Tocopherol) is a fat-soluble antioxidant, which has the protective effect of biological cell membranes from lipid peroxidation so that it may have an anti-inflammatory effect. Vitamin E supplements are useful in reducing and slowing kidney damage that occurs due to increased oxidative stress, also vitamin E prevents the decrease in levels of other antioxidants in the kidneys such as GSH, CAT, and SOD caused by cisplatin.\(^4\) The protective effect against ROS, other antioxidants and anti-inflammatory effects of vitamin E might reduce TNF-\(\alpha\) levels in the kidneys caused by cisplatin administration. Therefore, vitamin E is assumed to be a nephroprotective agent in subjects receiving cisplatin treatment.

OBJECTIVE

To analyze the protective effect of vitamin E on TNF-\(\alpha\) levels in white Wistar strains exposed to Cisplatin.

MATERIAL & METHODS

The design of this study was an experimental laboratory with post-test only control group design, with the evaluation of TNF-\(\alpha\) levels carried out after the animals were treated. The grouping of experimental animals was carried out by randomization, with repetition of 7 experimental animals in each group and there was a control group as a comparison (positive control and negative control).

Samples are grouped into 4 groups randomly by using random numbers to increase internal validity because this research is a case study (causality). Samples of male white rats (Rattus norvegicus) strain of Wistar, which were newly obtained from Lembaga Penelitian Terpadu (LPT) of Gadjah Mada University, Jogjakarta, began with an adaptation process in the cage/research environment for 2 weeks with a cycle of 12 hours of light, 12 hours of dark. The control group in this study included a negative control group (CN), which was given an injection of 1 cc intravenous normal saline 0.9% on the 7th day as a placebo, then on the 10th day the blood sample was taken. The positive control group (CP), which was given cisplatin treatment (Cisplatin, Kalbe Farma, Indonesia) at a dose of 5 mg/kg intraperitoneally, once on the 7th day. Treatment group (P1) was treated using cisplatin 5 mg/kg intra-peritoneally and Vitamine E 100 mg/KgBW, and Treatment group (P2) was treated using cisplatin 5 mg/kg intra-peritoneally and Vitamine E 200 mg/KgBW.

Blood samples were taken on the 10th day, intra-cardiac. Furthermore, TNF-\(\alpha\) levels were analyzed using ELISA. The TNF-\(\alpha\) value data will be tested for Kolmogorov-Smirnov normality to find out whether the data is normal or not and will also be tested for variance to find out whether the data variant is same or not. If the data distribution is normal and the variant is homogeneous, then the One-Way Anova hypothesis test is used, if the variant is not homogeneous, One-Way Anova Brown-Forsythe is used.

The hypothesis is determined based on the significance value obtained. If the significance value
<0.05, then the next step is to do a multiple comparison test or Post Hoc Test by LSD, which is to find out in more detail the pairs of treatment groups that are significantly different and those that are not significantly different. If the data variant is not homogeneous then the next step is to do a multiple comparison or post hoc test using Games-Howel to find out the comparison of differences between treatment groups. If there are differences, then proceed with the next statistical test to find out different data pairs (to see differences from each group). This test uses Mann Whitney as a further Kruskal Wallis test.

This study was significant if p-value <0.05. All data processing techniques were analyzed using Statistical Product and Service Solution 25 for Windows (SPSS 25) software.

RESULTS

In this study randomization of subjects was carried out to reduce research bias by using simple randomized sampling methods. Kolmogorov-Smirnov homogeneity test was conducted to assess the success of randomization. The results of normality weight data test subjects showed normal distribution were normal (p<0.05), therefore One-Way Anova was performed. One-Way Anova test showed that there were significant mean differences between groups with p<0.05. Mean data between groups was further analyzed to determine whether there were differences in variability using the Leven's Test, the result was a difference in variance between groups with p<0.05. Mean data between groups was further analyzed to determine whether there were differences in variability using the Leven's Test, the result was a difference in variance between groups (Table 1). The results found no mean difference between treatment groups (p>0.05). So it can be concluded that the randomization of subjects in this study has been successfully carried out. The sample characteristics were shown in table 1.

### Table 1. Sample body weight characteristics.

<table>
<thead>
<tr>
<th>Group</th>
<th>(Mean ± SD)</th>
<th>Normality</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CN</td>
<td>202.4 ± 2.9</td>
<td>0.160</td>
<td>0.506</td>
</tr>
<tr>
<td>CP</td>
<td>201.5 ± 4.1</td>
<td>0.173</td>
<td></td>
</tr>
<tr>
<td>P1</td>
<td>199.8 ± 2.4</td>
<td>0.210</td>
<td></td>
</tr>
<tr>
<td>P2</td>
<td>201.1 ± 2.9</td>
<td>0.224</td>
<td></td>
</tr>
</tbody>
</table>

In this study, a statistical test was performed using the mean absorbance value in the form of optical density (OD) obtained from the ELISA method with serum samples of research mice. The normality test was carried out using the Kolmogorov-Smirnov test, the results of the data distribution were normal (p<0.05), therefore One-Way Anova was performed. One-Way Anova test showed that there were significant mean differences between groups with p<0.05. Mean data between groups was further analyzed to determine whether there were differences in variability using the Leven's Test, the result was a difference in variance between groups with p<0.05. Furthermore, the Post Hoc Games-Howell test was carried out to compare the mean differences between study groups (Table 3).

### Table 2. Comparison of Tumour Necrosis Factor-α (TNF-α) levels in study subjects.

<table>
<thead>
<tr>
<th>Group</th>
<th>(Mean ± SD)</th>
<th>Lower Bound - Upper Bound</th>
<th>Normality</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CN</td>
<td>11.39 ± 0.65</td>
<td>10.70 – 12.08</td>
<td>0.200*</td>
<td>0.0001*</td>
</tr>
<tr>
<td>CP</td>
<td>31.10 ± 0.82</td>
<td>30.22 – 31.97</td>
<td>0.200*</td>
<td></td>
</tr>
<tr>
<td>P1</td>
<td>20.56 ± 0.09</td>
<td>20.46 – 20.65</td>
<td>0.200*</td>
<td></td>
</tr>
<tr>
<td>P2</td>
<td>20.45 ± 0.27</td>
<td>20.17 – 20.74</td>
<td>0.200*</td>
<td></td>
</tr>
</tbody>
</table>

### Table 3. Comparison of Tumour Necrosis Factor-α (TNF-α) levels between treatment groups.

<table>
<thead>
<tr>
<th>Comparison of TNF-α levels between groups</th>
<th>Mean Difference</th>
<th>Confidence interval 95%</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Lower bound</td>
<td>Upper bound</td>
</tr>
<tr>
<td>CN Vs CP</td>
<td>19.705*</td>
<td>9.49</td>
<td>37.17</td>
</tr>
<tr>
<td>CN Vs P1</td>
<td>9.165*</td>
<td>18.37</td>
<td>21.03</td>
</tr>
<tr>
<td>CN Vs P2</td>
<td>9.061*</td>
<td>8.09</td>
<td>10.03</td>
</tr>
<tr>
<td>CP Vs P1</td>
<td>10.540*</td>
<td>9.29</td>
<td>11.78</td>
</tr>
<tr>
<td>CP Vs P2</td>
<td>10.643*</td>
<td>9.41</td>
<td>11.87</td>
</tr>
<tr>
<td>P1 Vs P2</td>
<td>0.103</td>
<td>-13.84</td>
<td>13.84</td>
</tr>
</tbody>
</table>
From the results of the Post Hoc Games-Howell statistical analysis, it was found that there were differences in the mean TNF-α levels in the negative control group for all treatment groups with a p-value <0.05. There was also a significant difference in TNF-α levels in the positive control group for treatment group 1 and treatment 2 with p<0.05. On the other hand, further analysis showed that there was no significant difference between treatment group 1 and treatment group 2 (p>0.05) (Table 3).

DISCUSSION

Cisplatin (dichlorodiamino platinum) is an inorganic platinum-based chemotherapy agent that is widely used in the treatment of various malignant solid tumours. Cisplatin has been used in the treatment of testicular, ovarian, bladder, head and neck cancers, esophagus, lungs, breast, cervix, stomach, prostate cancer, Hodgkin’s and non-Hodgkin’s lymphoma, neuroblastoma, sarcoma, multiple myeloma, melanoma, and mesothelioma. The main limitation of cisplatin chemotherapy agent is the nephrotoxicity side effects about 25%-35% of patients experience a significant decline in kidney function after a single dose of cisplatin.\(^7\,8\)

Previous studies have suggested that pro-inflammatory cytokines such as TNF-α are involved in cisplatin-induced nephrotoxicity.\(^7\) TNF-α is also known as one of the main sources of nephrotoxicity in patients treated by cisplatin. TNF-α induction occurs when kidney tissue experiences a pathological condition which in turn leads to acute kidney failure. Various TNF-α inhibitors in mice induced with nephrotoxicity provide better progression in the occurrence of acute renal failure.\(^4\)

The use of cisplatin (5 mg/kgBW) in this study has shown a significant increase in TNF-α levels compared to controls. The results of this study are in accordance with the results of previous studies which showed that the cisplatin chemotherapy agent has the effect of nephrotoxicity through an increase in pro-inflammatory cytokines TNF-α.\(^7\,9\) Another study that used the same research design as this study was a study conducted by Liu et al., In 2006 which showed that intra-peritoneal cisplatin administration in mice would have an effect on nephrotoxicity and eventually there would be acute renal failure in mice.\(^10\) The dose used in this study is similar to the dose in previous studies that used doses are between 2-40 mg/kgBW with the end result of nephrotoxicity in rat kidneys.\(^4\,7\,9\)

Nephrotoxicity due to cisplatin can be caused by mitochondrial dysfunction and increased production of reactive oxygen species (ROS) through a respiratory chain that is disrupted by the cytochrome P450 (CYP) system.\(^11\) An increase in various oxygen radical species such as hydrogen peroxide H2O2 and superoxide anion O2 is known to cause an increase in mRNA from TNF-α.\(^11\) The TNF-α response invitro causes it to bind to two main TNF-α receptors, namely: TNFR1 and TNFR2. Both of these receptors will act as regulators of the process of apoptosis and proinflammation in kidney cells. TNFR1 will act as a ligand in the activation of various proapoptotic proteins and culminate in the expression of caspase effector 3 and 7 proteins.\(^12\) On the other hand, TNFR2 will act as a ligand for further expression of various cytokines and chemokines that support the inflammatory process. Thus, an increase in ROS expression after exposure to cisplatin can increase TNF-α expression which ultimately can work simultaneously in resulting in increased tubular cell death, kidney tissue damage and increased inflammation.\(^10\)

Various studies have been conducted to look for antioxidant agents that can prevent cisplatin nephrotoxicity without reducing its effectiveness. Vitamin E (α-tocopherol) is a natural antioxidant that can protect the integrity of cell membranes throughout the body from oxidation reactions caused by ROS.\(^13\) Several studies have shown the protective effect produced by vitamin E and its derivatives on nephrotoxicity and ototoxicity due to cisplatin. Giving vitamin E as a single agent or in combination with other antioxidant agents can cause changes in biomarkers of oxidative stress such as decreased levels of malondialdehyde, decrease in serum urea and serum creatinine and also increase the antioxidant activity of the kidney antioxidant enzymes renal catalyst glutathione S-transferase and superoxide dismutation.\(^14\)

In the results of this study, the exposure of low doses of vitamin E (100 mg/kgBW) gives a statistically significant difference in TNF-α levels compared to groups exposed to cisplatin alone. This is in line with previous studies that Vitamin E can reduce nephrotoxicity due to the cisplatin chemotherapy agent without interfering in its effectiveness.\(^15\) There is research that says otherwise, that vitamin E cannot be a nephroprotector against cisplatin toxicity. But in that study a mouse sample was given estrogen supplement, which can increase cisplatin toxicity.\(^4\)
Previous research concluded that Vitamin E can reduce the production of NO radicals and superoxide (endothelial cells and neutrophils) by inhibiting the production of protein kinase C. Besides having an antioxidant effect, vitamin E also has an anti-inflammatory effect. Several studies have shown that the administration of vitamin E can reduce the production of TNF-α in nephrotoxicity due to dichromate and acetic acid agents. This can support the results of this study where the provision of vitamin E can reduce TNF-α production in mice given cisplatin significantly. However, in this study the administration of high-dose Vitamin E (200 mg/kgBW) did not provide a significant difference in the reduction of TNF-α in mice given cisplatin when compared with the administration of low-dose vitamin E (100 mg/kgBW).

The increased dose of vitamin E in this study did not increase the effect on TNF-α. This can occur because vitamin E in the body can act as a dual agent. Vitamin E at the right dose can ward off free radicals by binding to free electrons, but in high doses vitamin E can act as a prooxidant molecule. This is caused by every time an anti-oxidative mechanism occurs, an a-Tocopherol radical (α-Toc*) will also be formed. Physiologically the increase in the radical effect of vitamin E can be avoided by the conversion of α-Toc* which involves vitamin C (L-Ascorbic Acid, Asa). Reduction of α-Toe* requires the enzymes Glutathione (GSH) in the cytosol and Ubiquinol (UQH2) in cell membranes which in turn convert these excess molecules into stable tocopherol molecules. This condition allows the absence of an effect of increasing the dose of vitamin E which leads to a decrease in TNF-α levels in the treatment.

CONCLUSION

TNF-α levels in mice given cisplatin was much higher compared with the control group. Vitamin E 100 and 200 mg/kgBW cause a decrease in TNF-α protein levels in mice injected with cisplatin when compared with controls. There is no difference in TNF-α levels in mice receiving vitamin E at doses of 100 and 200 mg/kgBW.

REFERENCES


